Laura E. Nagy received her BS in Biology in 1979 from Yale University and PhD in Nutrition in 1986 from the University of California Berkeley. She is currently a Professor of Molecular Medicine and Staff in Inflammation and Immunity and Gastroenterology and Hepatology at the Cleveland Clinic. She also holds adjunct Professor appointments at Case Western Reserve University and Cleveland State University. She is Director of the Liver Disease Research Center in the Lerner Research Institute at Cleveland Clinic. Dr.

Kyle Yuquimpo is a gastroenterology fellow and upcoming transplant hepatology fellow at the University of Kansas Medical Center in the physician scientist training pathway currently completing research training in the Weinman Lab. He is currently studying the effect of alcohol and high fat diet on macrophage evolution and development in the liver.

Bin Gao, M.D., PhD, is Chief of Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) in Bethesda, Maryland, USA. He received his medical training and Ph.D. in immunology from China, respectively. Following postdoctoral training at the NIAAA/NIH and Virginia Commonwealth University (VCU) School of Medicine, he served as a tenure track Assistant Professor at VCU from 1995 to 2000. In 2000, Dr.

Anwaar Saeed, MD, is an Associate Professor of Medicine and the Chief of Gastrointestinal Oncology at the University of Pittsburgh Medical Center (UPMC) and UPMC Hillman Cancer Center. Dr. Saeed's clinical research is focused on developmental therapeutics and immune modulatory approaches in gastrointestinal malignancies as well as immunoprevention in the high-risk gastrointestinal cancer populations. She is a prolific clinical researcher and multiple award winner.

I am a transplant hepatologist, clinical researcher, and Assistant Professor of Medicine at the University of North Carolina (UNC). I practice within the UNC Multidisciplinary HCC Clinic. The overall goal of my clinical work and research is to improve outcomes among patients with liver disease and hepatocellular carcinoma (HCC) by identifying risk factors for liver disease and HCC development, optimizing earlier disease detection and designing interventions to proactively address symptoms and liver-related decompensation related to HCC treatments.

Dr. Anjana Pillai is a Professor of Medicine and Surgery at the University of Chicago. She is the Director of University of Chicago's multidisciplinary liver tumor program, interim Medical Director of the Transplant Institute and the Program Director for the ACGME accredited Transplant Hepatology Fellowship. ​

Tamar Taddei, MD, FAASLD, is Professor of Medicine and Vice Chief (Digestive Diseases) at Yale School of Medicine and Chief of Digestive Diseases at the VA Connecticut Health Care System. She serves the VA National GI and Hepatology Program as Chair of the HCC Subcommittee of the VA Hepatology Field Advisory Board. Her clinical interests focus on developing systems and programs to deliver outstanding multidisciplinary care to people with liver cancer.

Veronica Nguyen, MD, is a Transplant Hepatologist at Inova Health System. She completed her Transplant Hepatology fellowship at MedStar Georgetown University Hospital. Dr. Nguyen is an active member of the American Association for the Study of Liver Diseases (AASLD) and has served on its Special Interest Group Steering Committee since 2022. She contributes to the field as a peer reviewer for journals including Transplantation, Clinical Liver Disease and ACG Case Reports Journal.

Maria Reig, MD, PhD, is an internationally recognized physician-scientist specializing in liver diseases and liver cancer. She is currently Head of the Hepatic Oncology Unit at Hospital Clínic Barcelona, Head of the Barcelona Clinic Liver Cancer (BCLC) group at IDIBAPS, and Head of the Hepatic Oncology Group at CIBEREHD. She is also a member of the CIBEREHD Steering Committee. Her work focuses on advancing clinical research, innovation, and treatment strategies for patients with hepatocellular carcinoma.

Dr Manon Allaire is Doctor of Medecine in La Pitié Salpétrière Hospital in Paris, headed by Pr Thabut. She focuses on teaching and research in hepatocellular carcinoma with focus in portal hypertension and systemic therapy. Dr Allaire obtained her medical degree in Hepatology and Gastroenterology in 2015 and her complementary medical degree in Medical Oncology in 2017. She is responsible of the Department of primary liver tumor in La Pitié Salpétrière Hospital, and of clinical and translational trials focus on primary liver tumor.